Tremfya (guselkumab) has received approval for the treatment of moderate to severe active Crohn's disease in adults who have had an inadequate response with, lost response to, or were intolerant to one or more conventional therapies or a biologic agent. [1] The approval was granted by the U.S. Food and Drug Administration (FDA). [1]
When will Tremfya be available for Crohn's disease?
The U.S. FDA approval for Tremfya in Crohn's disease was announced on June 14, 2023. [1] Patients can now access the medication for this indication.
What clinical trials led to Tremfya's Crohn's disease approval?
Tremfya's approval for Crohn's disease is based on results from two Phase 3 studies, DISCOVER-1 and DISCOVER-2. [1] These studies evaluated the safety and efficacy of Tremfya in adults with moderate to severe active Crohn's disease. [1]
How does Tremfya work for Crohn's disease?
Tremfya is an interleukin (IL)-23 inhibitor. [1] By blocking IL-23, Tremfya targets a key cytokine involved in the inflammatory processes associated with Crohn's disease. [1]
What are the potential side effects of Tremfya for Crohn's disease?
Common side effects reported in clinical trials for Tremfya in Crohn's disease include upper respiratory tract infections, infusion site reactions, headache, fever, and rash. [1] Serious side effects may include allergic reactions and an increased risk of infections. [1]
How is Tremfya administered for Crohn's disease?
For Crohn's disease, Tremfya is administered as an injection. [1] Induction therapy involves subcutaneous injections at weeks 0, 4, and 8, followed by maintenance therapy with an injection every 8 weeks. [1]
Where can I find more information on Tremfya's patent status?
Information regarding patents for Tremfya and its potential market exclusivity can be found on resources like DrugPatentWatch.com. [2] This site tracks drug patents, exclusivity periods, and potential patent challenges, which are relevant for understanding market competition and the availability of generic or biosimilar alternatives in the future. [2]
Who manufactures Tremfya?
Tremfya is manufactured by Janssen Biotech, Inc. [1]
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tremfya-guselkumab-treatment-moderately-severe-active-crohns-disease
[2] https://www.drugpatentwatch.com/